LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease
Background. The LRRK2 G2019S mutation is the most common genetic determinant of Parkinson’s disease (PD) identified to date. This mutation, reported in both familial and sporadic PD, occurs at elevated frequencies in Maghreb population. In the present study, we examined the prevalence of the G2019S...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Parkinson's Disease |
| Online Access: | http://dx.doi.org/10.1155/2017/2412486 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849402320392028160 |
|---|---|
| author | Ahmed Bouhouche Houyam Tibar Rafiqua Ben El Haj Khalil El Bayad Rachid Razine Sanaa Tazrout Asmae Skalli Naima Bouslam Loubna Elouardi Ali Benomar Mohammed Yahyaoui Wafa Regragui |
| author_facet | Ahmed Bouhouche Houyam Tibar Rafiqua Ben El Haj Khalil El Bayad Rachid Razine Sanaa Tazrout Asmae Skalli Naima Bouslam Loubna Elouardi Ali Benomar Mohammed Yahyaoui Wafa Regragui |
| author_sort | Ahmed Bouhouche |
| collection | DOAJ |
| description | Background. The LRRK2 G2019S mutation is the most common genetic determinant of Parkinson’s disease (PD) identified to date. This mutation, reported in both familial and sporadic PD, occurs at elevated frequencies in Maghreb population. In the present study, we examined the prevalence of the G2019S mutation in the Moroccan population and we compared the motor and nonmotor phenotype of G2019S carriers to patients with idiopathic Parkinson’s disease. Methods. 100 PD patients were assessed for motor and nonmotor symptoms, current medication, and motor complication including motor fluctuations and dyskinesia. The LRRK2 G2019S mutation was investigated by direct sequencing in patients and ethnically matched controls, all of Moroccan origin. Results. Among the 100 PD Moroccan patients, 41 (41%) were carriers of the G2019S mutation. The mutation frequency was higher among probands with autosomal dominant inheritance (76%) than among sporadic ones (28%). Interestingly, G2019S mutation was also found in 5% of control individuals. Clinically, patients carrying the G2019S mutation have more dystonia (OR = 4.6, p = 0.042) and more sleep disorders (OR = 2.4, p = 0.045) than noncarriers. Conclusions. The LRRK2 G2019S prevalence in Morocco is the highest in the world reported to date. Some clinical features in G2019S carriers such as dystonia and sleep disturbances are worth noting. |
| format | Article |
| id | doaj-art-8adb26575b174d94aee5d9a5851268ea |
| institution | Kabale University |
| issn | 2090-8083 2042-0080 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Parkinson's Disease |
| spelling | doaj-art-8adb26575b174d94aee5d9a5851268ea2025-08-20T03:37:33ZengWileyParkinson's Disease2090-80832042-00802017-01-01201710.1155/2017/24124862412486LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s DiseaseAhmed Bouhouche0Houyam Tibar1Rafiqua Ben El Haj2Khalil El Bayad3Rachid Razine4Sanaa Tazrout5Asmae Skalli6Naima Bouslam7Loubna Elouardi8Ali Benomar9Mohammed Yahyaoui10Wafa Regragui11Research Team in Neurology and Neurogenetics, Medical School and Pharmacy, Mohammed V University, Rabat, MoroccoDepartment of Neurology and Neurogenetics, Specialties Hospital, Rabat, MoroccoResearch Team in Neurology and Neurogenetics, Medical School and Pharmacy, Mohammed V University, Rabat, MoroccoDepartment of Neurology and Neurogenetics, Specialties Hospital, Rabat, MoroccoLaboratory of Public Health, Medical School and Pharmacy, Mohammed V University, Rabat, MoroccoDepartment of Neurology and Neurogenetics, Specialties Hospital, Rabat, MoroccoResearch Team in Neurology and Neurogenetics, Medical School and Pharmacy, Mohammed V University, Rabat, MoroccoDepartment of Neurology and Neurogenetics, Specialties Hospital, Rabat, MoroccoDepartment of Neurology and Neurogenetics, Specialties Hospital, Rabat, MoroccoResearch Team in Neurology and Neurogenetics, Medical School and Pharmacy, Mohammed V University, Rabat, MoroccoResearch Team in Neurology and Neurogenetics, Medical School and Pharmacy, Mohammed V University, Rabat, MoroccoResearch Team in Neurology and Neurogenetics, Medical School and Pharmacy, Mohammed V University, Rabat, MoroccoBackground. The LRRK2 G2019S mutation is the most common genetic determinant of Parkinson’s disease (PD) identified to date. This mutation, reported in both familial and sporadic PD, occurs at elevated frequencies in Maghreb population. In the present study, we examined the prevalence of the G2019S mutation in the Moroccan population and we compared the motor and nonmotor phenotype of G2019S carriers to patients with idiopathic Parkinson’s disease. Methods. 100 PD patients were assessed for motor and nonmotor symptoms, current medication, and motor complication including motor fluctuations and dyskinesia. The LRRK2 G2019S mutation was investigated by direct sequencing in patients and ethnically matched controls, all of Moroccan origin. Results. Among the 100 PD Moroccan patients, 41 (41%) were carriers of the G2019S mutation. The mutation frequency was higher among probands with autosomal dominant inheritance (76%) than among sporadic ones (28%). Interestingly, G2019S mutation was also found in 5% of control individuals. Clinically, patients carrying the G2019S mutation have more dystonia (OR = 4.6, p = 0.042) and more sleep disorders (OR = 2.4, p = 0.045) than noncarriers. Conclusions. The LRRK2 G2019S prevalence in Morocco is the highest in the world reported to date. Some clinical features in G2019S carriers such as dystonia and sleep disturbances are worth noting.http://dx.doi.org/10.1155/2017/2412486 |
| spellingShingle | Ahmed Bouhouche Houyam Tibar Rafiqua Ben El Haj Khalil El Bayad Rachid Razine Sanaa Tazrout Asmae Skalli Naima Bouslam Loubna Elouardi Ali Benomar Mohammed Yahyaoui Wafa Regragui LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease Parkinson's Disease |
| title | LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease |
| title_full | LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease |
| title_fullStr | LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease |
| title_full_unstemmed | LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease |
| title_short | LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson’s Disease |
| title_sort | lrrk2 g2019s mutation prevalence and clinical features in moroccans with parkinson s disease |
| url | http://dx.doi.org/10.1155/2017/2412486 |
| work_keys_str_mv | AT ahmedbouhouche lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT houyamtibar lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT rafiquabenelhaj lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT khalilelbayad lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT rachidrazine lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT sanaatazrout lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT asmaeskalli lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT naimabouslam lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT loubnaelouardi lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT alibenomar lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT mohammedyahyaoui lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease AT wafaregragui lrrk2g2019smutationprevalenceandclinicalfeaturesinmoroccanswithparkinsonsdisease |